Ren, 2002 - Google Patents
Use of modulators of airways inflammation in patients with CFRen, 2002
- Document ID
- 1464894258464291384
- Author
- Ren C
- Publication year
- Publication venue
- Clinical reviews in allergy & immunology
External Links
Snippet
One of the hallmarks of cystic fibrosis (CF) lung disease is the presence of intense, neutrophil-dominated airway inflammation, and many researchers have focused on developing therapies to reduce inflammation in CF lung disease. Systemic corticosteroids …
- 206010061218 Inflammation 0 title abstract description 26
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ratjen et al. | Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis | |
| Li et al. | Probiotic fermentation of Ganoderma lucidum fruiting body extracts promoted its immunostimulatory activity in mice with dexamethasone-induced immunosuppression | |
| AU4422197A (en) | Delivery of therapeutic gene products by intestinal cell expression | |
| WO2020147475A1 (en) | Use of rhodococcus ruber product in treatment of recurrent aphthous ulcer | |
| JP2002515454A (en) | Method and means for preventing or treating inflammation or pruritus | |
| CN114657084B (en) | Bifidobacterium longum for relieving ulcerative colitis and its application | |
| CN112402459B (en) | Application of clostridium pralatum in relieving allergic asthma and rhinitis Th2 reaction | |
| US20230136694A1 (en) | Pharmaceutical composition for preventing or treating atopic disease containing akkermansia muciniphila strain | |
| BR112021001206A2 (en) | use of gram negative species to treat atopic dermatitis | |
| Ren | Use of modulators of airways inflammation in patients with CF | |
| CN113546089B (en) | Application of 1-ethyl-3, 7-dimethyl xanthine in preparation of medicine for treating pneumonia | |
| Perić et al. | Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis | |
| EP4417213A1 (en) | Use of bacteroides fragilis in prevention and treatment of cancer-related diarrhea | |
| CN114369146B (en) | Acremonium Amuc-2172 protein and preparation method and application thereof | |
| CN113413402B (en) | Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection disease | |
| Morgan et al. | Pulmonary immunologic features of alveolar septal amyloidosis associated with multiple myeloma | |
| JPH09263539A (en) | Therapeutic agent for dermatopathy having antifungal action | |
| CN115518079A (en) | Application of probiotics and outer membrane vesicles thereof in preparation of preparation for preventing and treating bronchial asthma | |
| CN116139258B (en) | Use of roxburghii SOD in preparing medicine for preventing or treating intestinal diseases | |
| JP2855283B2 (en) | Anti-ulcer agent and method for producing the same | |
| WO2019205506A1 (en) | Egg-shaped bacteroides for relieving endotoxin infection and application thereof | |
| CN107485637A (en) | Application of the total glycosides enzymolysis product of Momordica grosvenori in anti-hepatic fibrosis medicines | |
| CN105343132A (en) | Composition and medicine for treating colitis and preparation method thereof | |
| CN118415297B (en) | Application of postbiotic nutrient solution in increasing the number of white blood cells and platelets, improving immunosuppression and intestinal damage caused by chemotherapy drugs, and preparation method thereof | |
| CN113304175B (en) | Application of butyric acid bacillus in preparing medicine for preventing and/or treating kawasaki disease |